1. Home
  2. EWCZ vs ENGN Comparison

EWCZ vs ENGN Comparison

Compare EWCZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWCZ
  • ENGN
  • Stock Information
  • Founded
  • EWCZ 2004
  • ENGN 1999
  • Country
  • EWCZ United States
  • ENGN Canada
  • Employees
  • EWCZ N/A
  • ENGN N/A
  • Industry
  • EWCZ Package Goods/Cosmetics
  • ENGN
  • Sector
  • EWCZ Consumer Discretionary
  • ENGN
  • Exchange
  • EWCZ Nasdaq
  • ENGN Nasdaq
  • Market Cap
  • EWCZ 300.3M
  • ENGN 297.7M
  • IPO Year
  • EWCZ 2021
  • ENGN N/A
  • Fundamental
  • Price
  • EWCZ $3.84
  • ENGN $5.25
  • Analyst Decision
  • EWCZ Buy
  • ENGN Buy
  • Analyst Count
  • EWCZ 7
  • ENGN 9
  • Target Price
  • EWCZ $6.07
  • ENGN $25.22
  • AVG Volume (30 Days)
  • EWCZ 621.9K
  • ENGN 36.4K
  • Earning Date
  • EWCZ 03-11-2025
  • ENGN 03-10-2025
  • Dividend Yield
  • EWCZ N/A
  • ENGN N/A
  • EPS Growth
  • EWCZ 29.60
  • ENGN N/A
  • EPS
  • EWCZ 0.22
  • ENGN N/A
  • Revenue
  • EWCZ $216,916,000.00
  • ENGN N/A
  • Revenue This Year
  • EWCZ $5.65
  • ENGN N/A
  • Revenue Next Year
  • EWCZ $4.11
  • ENGN N/A
  • P/E Ratio
  • EWCZ $19.08
  • ENGN N/A
  • Revenue Growth
  • EWCZ N/A
  • ENGN N/A
  • 52 Week Low
  • EWCZ $2.72
  • ENGN $4.42
  • 52 Week High
  • EWCZ $13.31
  • ENGN $18.40
  • Technical
  • Relative Strength Index (RSI)
  • EWCZ 22.89
  • ENGN 39.24
  • Support Level
  • EWCZ $4.08
  • ENGN $4.90
  • Resistance Level
  • EWCZ $4.72
  • ENGN $5.46
  • Average True Range (ATR)
  • EWCZ 0.40
  • ENGN 0.49
  • MACD
  • EWCZ -0.15
  • ENGN 0.02
  • Stochastic Oscillator
  • EWCZ 40.31
  • ENGN 31.85

About EWCZ European Wax Center Inc.

European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: